WELLESLEY, Mass.—(BUSINESS WIRE)—Allurion Technologies announced today that its flagship product, Elipse, has received the prestigious Emerging Technology Innovation Award from the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Elipse is the world’s first procedureless™ intragastric balloon: it is placed and removed without surgery, endoscopy or anesthesia. It is the first intragastric balloon to receive this award. Elipse received European Union CE marking in late 2015 and is now available at leading weight loss centers in the United Kingdom, Italy and France. Plans for commercial expansion within Europe and in the Middle East are underway. Elipse is not yet approved by the FDA and is not available in the United States.“The medical community has been looking for innovative tools like Elipse to aid in the fight against overweight and obesity”
Elipse was one of 13 technologies chosen to present to an expert panel of gastrointestinal and endoscopic surgeons. The panel voted Elipse the top emerging technology of SAGES 2016 following a presentation by Allurion Co-Founder and Chief Scientific Officer Dr. Shantanu Gaur. “We are honored that our novel approach to weight loss has been recognized by the physicians of SAGES,” said Dr. Gaur. “This award adds to our momentum as we expand awareness of Elipse among physicians and consumers.”
“The medical community has been looking for innovative tools like Elipse to aid in the fight against overweight and obesity” said Jonathan Wecker, Chief Executive Officer of Allurion. “Without the cost and invasiveness of surgery, endoscopy and anesthesia, this new option vastly expands access to intragastric balloons.”
Allurion Co-Founder and President Dr. Samuel Levy added that “physicians and consumers involved in our initial European launch have been extremely pleased, and we look forward to continued success as Elipse is rolled out to new weight loss centers and new geographies.”
Elipse is a procedureless intragastric balloon: it is placed and removed without surgery, endoscopy or anesthesia. It is offered by physicians in conjunction with a medically supervised weight loss program. The Elipse balloon is made of a thin, flexible polymer film. The device is swallowed in a capsule and filled with liquid through a thin delivery catheter, which is then detached. Elipse remains in the stomach for approximately four months after which the balloon opens, allowing it to empty and pass naturally from the body. A clinical study of Elipse in individuals with a Body Mass Index (BMI) between 27 and 40 showed an average weight loss of 10 kilograms (22 pounds), with participants losing 39 percent of their excess weight and eight centimeters from their waist circumference. Participants also saw improvements in their triglycerides, haemoglobin A1c (HbA1c) and quality of life. Learn more and see an animation of Elipse in action here.
About Allurion Technologies
Allurion Technologies is dedicated to developing less invasive treatments for overweight and obese individuals. The company’s flagship product, Elipse, is an intragastric balloon that resides in the stomach, enabling weight reduction. Allurion is funded by private investors and the Massachusetts Life Sciences Center. Learn more about Elipse and Allurion online at www.allurion.com or on Twitter @alluriontech.